Method and chromatography system for determining amount and purity of multimeric protein
The novel chromatography system with a switching valve and dual affinity matrices addresses the inefficiencies in separating and quantifying bispecific antibodies, achieving enhanced purity and yield by exploiting differential protein affinities and pH conditions.
Patent Information
- Application Number
- JP2024117397
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-08-17
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-06
AI Technical Summary
Current methods for evaluating the amount and purity of multimeric proteins, particularly bispecific antibodies, are inefficient and lack the speed and accuracy required for commercial-scale production, especially in separating heterodimers from homodimers during antibody purification processes.
A novel chromatography system utilizing a switching valve to connect two affinity matrices (protein A and protein G) allows for sequential elution of proteins based on their differential affinities, enabling precise quantification and purification of heterodimeric proteins by bypassing matrices where they do not bind, and using pH and mobile phase modifiers to achieve selective elution.
The system effectively separates and quantifies heterodimeric proteins from homodimeric impurities, enhancing the efficiency and accuracy of quality control in antibody production, thereby improving the purity and yield of bispecific antibodies.
Smart Images

Figure 2024156725000004 
Figure 2024156725000005 
Figure 2024156725000006
Abstract
Description
[Technical field]
[0001] The present invention relates to a chromatographic method for assessing the amount and / or purity of a multimeric protein in a sample. The present invention relates to a chromatography system and method, the chromatography system including a switching valve ( Two different affinity chromatography columns connected via a switch valve Including Trix. [Background technology]
[0002] Bispecific antibodies bind to two different epitopes simultaneously on the same or different antigens. The binding of multiple targets by a single molecule is particularly It is an attractive therapeutic concept in the fields of oncology and autoimmune diseases. An application is cancer immunotherapy, where bispecific antibodies are used to bind cytotoxic and a target, such as a tumor cell, that is to be destroyed. Furthermore, targeting multiple molecules avoids the regulation of parallel pathways and improves therapeutic response. Most pathologies are complex, multifaceted, and systemic. Because they have an effect, binding or blocking multiple targets in the pathway can halt the disease. This could be beneficial for
[0003] Several bispecific antibody formats have been proposed and are currently under development. One of the formats has an improved pharmacokinetic profile and minimal immunogenicity It is based on standard fully human IgG antibodies (see U.S. Pat. No. 8,586,713 and WO2016 / 018 740), which is shown diagrammatically in Figure 1. It combines one common light chain with two different heavy chains. One of the heavy chains is coupled to a substituted Fc sequence (hereinafter "Fc *), which contains H435R / Y436F (according to the EU numbering system) in the CH3 domain. According to the IMGT exon numbering system, the H95R / Y96F substitution leads to a nucleotide sequence that is linked to protein A. Co-expression of Fc* heavy chains and Fc heavy chains with a common light chain results in Three products were generated, two of which (FcFc and Fc*Fc*) were homodimers with respect to the heavy chain. One (FcFc*) is the desired heterodimeric bispecific product. The protein binding is more efficient than that of the FcFc heavy chain homodimer, which binds more efficiently, or the weaker Fc*Fc* homodimer. Due to its intermediate binding affinity to Fc-binding proteins such as ribonuclease A, the Fc* sequence is Allows selective purification of FcFc* bispecific products on affinity chromatography columns To perform.
[0004] Another antibody format is the so-called "one-arm" antibody described in WO2013 / 166604. The heterodimeric antibody is a "heterodimeric" antibody, which is shown diagrammatically in FIG. 2A. This heterodimeric antibody can be, for example, It consists of two different heavy chains and only one light chain. The heavy chain contains the Fc* sequence, whereas the heavy chain without the light chain contains the normal Fc sequence. The reaction mixture produced three products: two homodimers (FcFc and Fc*Fc*) and the desired The heterodimeric FcFc* product can be isolated using affinity chromatography. can be separated.
[0005] Yet another possible antibody format is an antibody having a C-terminal single chain variable region fragment (ScFv). The constructs are shown diagrammatically in FIG. 2B. These antibodies can be monospecific or bispecific. It may be heteromeric and contain a single common light chain and two different heavy chains. The heavy chain has an Fc* sequence and is linked to an ScFv, while the other heavy chain has a native Fc sequence and does not have an ScFv. In this example, the heavy chain with the ScFv construct has a native Fc sequence and the Fc* heavy chain does not have the ScFv. Additional mutations that prevent binding to affinity columns are present, similar to having an Fc* mutation. Further examples of mutations in the heavy chain variable region (VH) on the nucleotide sequence of the nucleotide sequence are described in, for example, U.S. Pat. No. 9,493, 563 (VH3 and Fc mutations are provided in IMGT 3, 5, 7, 20, 22, 26, 27, 79, 81, 84, 84.2, 85.1, 86, 90), which are incorporated by reference in their entireties. As in the above example, the ternary mixture of FcFc* heterodimers and FcFc and Fc*Fc* homodimers The compounds can be separated using differential binding affinity chromatography.
[0006] In the field of commercial-scale production of bispecific antibodies, various steps in antibody production and purification are There is a need to assess the relative and absolute amount and purity of the heterodimer in this To achieve this, an effective separation between the heterodimer and the two homodimer impurities is desired. Additionally, it is important to improve the speed and accuracy of quality control measurements during cell culture and antibody purification processes. The present invention provides novel chromatography systems and methods. This and other needs will be addressed by:
[0007] The foregoing discussion has been presented solely to provide a better understanding of the nature of the problems facing the art. and should not be construed as admissions of prior art in any manner whatsoever. The disclosure of any such references should not be construed as a substitute for the express written consent of the present application, and citation of any references herein shall not be deemed to be in any way construed as a substitute for the express written consent of the present application. This should not be construed as an admission that any of the above constitutes "prior art" to the application. Summary of the Invention
[0008] Various non-limiting aspects and embodiments of the invention are described below.
[0009] The present invention relates to a novel chromatography system including a switching valve, and a method for detecting heterogeneous ions in a sample. Methods for quantitatively assessing the amount and / or purity of a dimer fraction are described.
[0010] In one embodiment, the present invention provides a method for producing a protein comprising the steps of: Quantify the amount and / or purity of a protein in a sample, including mixtures with protein impurities wherein the protein and the first impurity are coupled to a first affinity The second impurity is substantially bound to the first affinity matrix. and binding to a second affinity matrix, the method comprising the steps of:
[0011] a. A first affinity matrix, a second affinity matrix, and a test applying the sample to a chromatography system including a detector, wherein a first The affinity matrix is connected to a second affinity matrix via a switching valve. Continuously connected, process;
[0012] b. removing a second impurity from the first affinity matrix under a first set of conditions; eluting the antibody onto an affinity matrix;
[0013] c. Switch the diverter valve to bypass the second affinity matrix and The protein is eluted through a detector under set conditions, and the amount of eluted protein is measured. determining;
[0014] d. eluting the first impurity through a detector under a third set of conditions; determining the amount of pure matter;
[0015] e. detecting the second impurity from the second affinity matrix under a third set of conditions. eluting the second impurity through a vessel and determining the amount of the eluted second impurity; and
[0016] f. Quantifying the amount and / or purity of protein in the sample.
[0017] In one embodiment, the protein is a multimeric protein, for example an antibody. In one embodiment, the protein is an antibody of interest and the first and second protein impurities are The object may be a multimeric protein, e.g., a protein that may or may not be structurally related to an antibody of interest. In one embodiment, the protein is a bispecific antibody, i.e., a heterodimer. the first protein impurity is a first homodimeric protein, and the second protein impurity is a second homodimeric protein. The protein impurity is a second homodimeric protein. In some cases, a multimeric protein A mixture of proteins, such as Chinese Hamster Ovary (CHO) cells in cell culture, It is produced by several eukaryotic cells.
[0018] In one embodiment, the protein is bound to a first affinity matrix. In one embodiment, the protein is a heterodimeric protein. the first protein impurity is a first homodimeric protein and the second protein impurity is a The protein impurity is a second homodimeric protein, which is a heterodimeric protein and a first homodimeric protein. The homodimeric protein binds to the first affinity matrix and binds to the second homodimeric protein. The protein does not substantially bind to the first affinity matrix and binds to the second affinity matrix. Binds to Trix.
[0019] In one embodiment, the protein comprises a first immunoglobulin CH3 domain and a second immunoglobulin CH3 domain. an immunoglobulin CH3 domain, wherein the first and second immunoglobulin CH3 domains The affinity matrix has different affinities for the first affinity matrix, and the sample is A protein containing two first CH3 domains and a protein containing two second CH3 domains. This includes mixtures containing cellulose and cellulose acetate.
[0020] In one embodiment, the second CH3 domain comprises the amino acids H435R and Y436F (according to the EU numbering system). ; H95R / Y96F according to the IMGT exon numbering system. In this state, the second CH3 domain is H435R (according to the EU numbering system; IMGT exon numbering system). In some embodiments, the second CH3 comprises an amino acid substitution (H95R according to the ELISA system). The domain is H435R (according to the EU numbering system; and containing an amino acid substitution (e.g., H95R) and is selected from Protein A, Protein G, Protein L, or their These antibodies have weak or no detectable binding to Fc-binding ligands such as derivatives of
[0021] In one embodiment, the protein is an antibody. is a bispecific antibody.
[0022] In one embodiment, the first affinity matrix comprises Protein A and the second affinity matrix comprises Protein A. The affinity matrix contains Protein G.
[0023] In one embodiment, the first set of conditions comprises a first pH and the second set of conditions comprises a second pH. and the third set of conditions comprises a third pH. In one embodiment, the second pH is lower than the first pH. and the third pH is lower than the second pH. In one embodiment, the first pH is from about pH 5.0 to about pH 7.4; The second pH is from about pH 4.3 to about pH 5.6, and the third pH is from about pH 2.0 to about pH 2.8.
[0024] In one embodiment, a first set of conditions, a second set of conditions, and a third set of conditions In one embodiment, the mobile phase modifier is LiCl, NaCl, KCl, MgC The salt buffer is selected from CaCl2 and CaCl2 buffers.
[0025] In another embodiment, a heterodimeric protein, a first homodimeric protein, and a second The amount and / or amount of heterodimeric protein in a sample, including a mixture with homodimeric proteins Alternatively, a method for quantifying the purity of a heterodimeric protein and a first The homodimeric protein binds to the first affinity matrix and the second homodimeric protein binds to the second affinity matrix. The protein does not substantially bind to the first affinity matrix and is bound to the second affinity matrix. The method comprises the steps of: a. A first affinity matrix, a second affinity matrix, and a test applying the sample to a chromatography system including a first affinity detector; The T-matrix is connected in series to a second affinity matrix via a switching valve. The process being carried out; b. Removal of a second homodimeric protein from a first affinity matrix under a first set of conditions. eluting the protein onto a second affinity matrix; c) Switch the switching valve to bypass the second affinity matrix and The heterodimeric protein was eluted through the detector under the same conditions, and the eluted protein was determining the amount of protein; d. eluting the first homodimeric protein through a detector under a third set of conditions; determining the amount of the eluted first impurity; e. Removing a second homodimer tag from the second affinity matrix under a third set of conditions. eluting the protein through a detector and determining the amount of the eluted second impurity; and Beauty f. Quantifying the amount and / or purity of protein in the sample.
[0026] In yet another embodiment, a heterodimeric protein and a first homodimeric protein , the amount of the heterodimeric protein in the sample, including a mixture with a second homodimeric protein. and / or a method for quantifying the purity of a heterodimeric protein and The first homodimeric protein binds to the Protein A matrix, and the second homodimeric protein binds to the Protein A matrix. The protein binds substantially but not to the Protein A matrix but to the Protein G matrix. and the method comprises the steps of: a. Chromatography containing Protein A matrix, Protein G matrix, and detector applying the sample to a lithography system, the Protein A matrix being connected serially to a Protein G matrix via a valve; b. Removal of a second homodimeric protein from the Protein A matrix under a first set of conditions. eluting the antibody onto a protein G matrix; c Switch the diverter valve to bypass the Protein G matrix and allow the second set of Under the conditions, the heterodimeric protein is eluted through the detector, and the amount of eluted protein is measured. determining a d. eluting the first homodimeric protein through a detector under a third set of conditions; determining the amount of the eluted first impurity; e. Removal of a second homogenate from the Protein G affinity matrix under a third set of conditions. eluting the monomeric protein through a detector and determining the amount of the eluted second impurity. ; and f. Quantifying the amount and / or purity of protein in the sample.
[0027] In one embodiment, the heterodimeric protein comprises FcFc* and the first homodimeric protein The first homodimeric protein contains FcFc and the second homodimeric protein contains Fc*Fc*.
[0028] In another embodiment, the first affinity matrix, the second affinity matrix and a detector, wherein the first affinity column is a first affinity column. The affinity matrix, the second affinity matrix and the detector are each It is connected via a valve.
[0029] In another embodiment, the method comprises the steps of: (i) a Protein A chromatography column; and (ii) a Protein G chromatography column. (iii) a UV detector, a charged aerosol detector, and / or a mass spectrometry column; and a detector including an HPLC column equipped with a mass spectrometer. Here, Protein A chromatography column, Protein G chromatography column Each of the rams and detectors is connected via a switching valve.
[0030] These and other aspects of the invention are set forth in the following detailed description of the invention, including the appended claims. This will become clear to those skilled in the art upon reading the description. [Brief description of the drawings]
[0031] [Figure 1] Figure 1 is a schematic diagram of a bispecific antibody format suitable for separation by the methods of the invention, based on a standard fully human IgG antibody with one common light chain and two different heavy chains, one containing an Fc* mutation and one with native (Fc) sequence. Note that one representative example is depicted and that the Fc* mutation can be incorporated into either the first or second heavy chain.
[0032] [Figure 2A] Figures 2A and 2B show schematic diagrams of two further antibody formats suitable for separation according to embodiments of the invention: Figure 2(A) shows a heterodimeric "one-arm" antibody consisting of two different heavy chains and only one light chain, where one heavy chain does not contain a Fab fragment (e.g., contains only the heavy chain constant domain). [Figure 2B] Figure 2(B) shows two exemplary antibody constructs with C-terminal single chain variable fragments (ScFv). Fc* mutations can be incorporated into either the first or second heavy chain (constant domain) polypeptide.
[0033] [Diagram 3] FIG. 3 shows titer chromatograms illustrating the separation of a mixture of bispecific antibodies and monomeric impurities using a system according to one embodiment of the present disclosure according to the methods of the present disclosure.
[0034] [Figure 4A] Figures 4(A) and 4(B) show schematic diagrams of an exemplary chromatography system according to one embodiment of the present disclosure. In one exemplary system shown in Figure 4(A), an autosampler is connected to a first affinity matrix (column), which is connected to a second affinity matrix (column) and a detector via a switching valve. In the illustrated configuration, the switching valve is arranged to serially connect the first column to the second column, and the eluent flows through the first column onto the second column and subsequently through the detector for quantification. [Figure 4B] In another exemplary system shown in Figure 4(B), an autosampler is connected to a first affinity matrix (column), which is connected to a second affinity matrix (column) via a switching valve. A detector is connected via a switching valve in a bypass (no column) configuration, where the switching valve either connects the first column to a second column which is in turn connected to a detector, or bypasses the second column and connects the first column directly to the detector.
[0035] [Diagram 5] 5 shows a bispecific antibody titer / purity setup according to one embodiment of the present disclosure. The schematic shows the solvent degasser, solvent manager, sample manager, column compartment manager, and detector.
[0036] [Figure 6]6 shows an exemplary chromatography system according to one embodiment of the present disclosure. In this exemplary column section of the system, a sample travels through several serially connected columns containing a first affinity matrix, followed by several serially connected columns containing a second affinity matrix. A switching valve connects the first set of columns to the second set of columns.
[0037] [Figure 7] FIG. 7 depicts an alternative schematic diagram of an exemplary chromatography system according to one embodiment of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0038] Detailed embodiments of the present invention are disclosed herein. However, the disclosed embodiments may vary. It should be understood that these are merely exemplary of the invention that may be embodied in various forms. Each of the examples provided in relation to various embodiments of the present invention is intended to be illustrative and not restrictive. It is therefore not intended that the specific structural and The functional details should not be construed as limiting, but merely as a guide for those skilled in the art to practice the present invention. The present disclosure should be interpreted as a representative basis for providing instructions for individual applications.
[0039] Unless otherwise defined, all technical and scientific terms used herein are , have the same meaning as commonly understood by a person skilled in the art to which the present invention pertains. Any methods and materials similar or equivalent to those described herein may be used in the practice of the present invention. or tests, but specific methods and materials are described herein. explain.
[0040] As used in this specification and the appended claims, the singular forms "a," "an," " and "the" include plural references unless the context clearly indicates otherwise. Thus, for example, For example, reference to "a method" refers to any method described herein and / or incorporating the present disclosure. One or more methods and / or processes of the kind that will become apparent to those skilled in the art upon reading the present invention. Includes the process.
[0041] Non-limiting examples of proteins suitable for separation using the methods of the present invention include heterodimers, Monomeric antibodies include, for example, bispecific antibodies, one-arm antibodies, and ScFv antibodies. Bispecific antibodies generally include, but are not limited to, two different heavy chains, each of which is a 2-antibody. on different molecules (e.g., two different antigens, or an antigen and a T cell receptor), or on the same Specifically bind to different epitopes on the same molecule (e.g., on the same antigen). An antibody selectively binds to two different epitopes (a first epitope and a second epitope). In the case where the affinity of the first heavy chain for the first epitope can be determined by the affinity of the first heavy chain, the affinity of the first heavy chain for the first epitope can be determined by the affinity of the first heavy chain. at least one to two or three or four orders of magnitude lower than the affinity for the second epitope of The epitopes recognized by bispecific antibodies may be the same or different. The antibodies may be on different targets (e.g., on the same or different proteins). For example, antibodies can be created by combining heavy chains that recognize different epitopes of the same antigen. For example, a fusion protein encoding heavy chain variable sequences that recognize different epitopes of the same antigen can be prepared. The nucleic acid sequence can be fused to a nucleic acid sequence encoding a different heavy chain constant region, such Such sequences can be expressed in cells that express immunoglobulin light chains. Each bispecific antibody has three heavy chain CDRs followed (N- to C-terminus) by a CH1 domain. It consists of two heavy chains with main, hinge, CH2 and CH3 domains and an antigen-binding domain. Each heavy chain can be associated with a different heavy chain, but does not confer any specificity. and capable of binding to one or more epitopes bound by the heavy chain antigen-binding region. or each heavy chain can associate with one or both epitopes. Some antibodies have an immunoglobulin light chain that allows binding of both heavy chains.
[0042] The term "Fc-containing protein" refers to an antibody, bispecific antibody, immunoadhesin, etc. and other binding proteins that contain at least functional portions of the immunoglobulin CH2 and CH3 regions. "Functional portion" includes Fc receptors (e.g., FcγR; or FcRn, i.e., It is believed that the antibodies can bind to the Fc receptor (the primary Fc receptor) and / or are involved in the activation of complement. If the CH2 and CH3 regions are capable of binding to any Fc receptor, Deletions, substitutions, and / or insertions that render the antibody unable to activate complement or other modifications, the CH2 and CH3 regions are not functional.
[0043] The Fc-containing protein can contain modifications in the immunoglobulin domain, which , where the modification affects one or more effector functions of the binding protein (e.g., Fc γR binding, FcRn binding (and thus half-life), and / or CDC activity) Such modifications include, but are not limited to, modifications of the immunoglobulin constant region. The following modifications and combinations thereof according to EU numbering are included: 238, 239, 248, 249, 250, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 297, 298, 301, 303, 305, 307, 308, 309, 311, 312, 315, 318, 320, 322, 324, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 337, 338, 339, 340, 342, 344, 356, 358, 359, 360, 361, 362, 373, 375, 376, 378, 380, 382, 383, 384, 386, 388, 389, 398, 414, 416, 419, 428, 430, 433, 434, 435, 437, 438 and 439.
[0044] For example, but not by way of limitation, the binding protein can be an Fc-containing protein and can be enhanced. showed improved serum half-life (compared to the same Fc-containing protein without the above modification(s)). ), positions 250 (e.g. E or Q); 250 and 428 (e.g. L or F); 252 (e.g. L / Y / F / W or T), 254 (e.g. S or T) and 256 (e.g. S / R / Q / E / D or T) or 428 and / or 433 (e.g. L / R / SI / P / Q or K) and / or 434 (e.g. or modifications in 250 and / or 428; or modifications in 307 or at 308 (e.g., 308F, V308F) and 434. In another example, the modifications are , 428L (e.g., M428L) and 434S (e.g., N434S) modifications; 428L, 2591 (e.g., V259I) and 308 F (e.g., V308F); 433K (e.g., H433K) and 434 (e.g., 434Y) Modifications; 252, 254, and 256 (e.g., 252Y, 254T, and 256E); 250Q and 428L (e.g., T250Q and M428L); modifications of 307 and / or 308 (e.g., 308F or 308 P).
[0045] The terms "star substitution", "Fc*", and "HC*" refer to Protein A, Protein G, Binding to the Fc domain of immunoglobulins, such as protein L or their derivatives Bacterial proteins known to be involved in the synthesis of ribozymes (e.g., Choe, W., incorporated herein by reference) are known to be involved in the synthesis of ribozymes (e.g., Choe, W., , et al. 2016, Materials 9, 994, doi: 10.3390 / ma9120994 Molecules containing mutations that abolish binding to SpA mimetic affinity ligands (see Immunoglobulin A). immunoglobulin heavy chains, Fc fragments, Fc-containing molecules, etc. The protein contains modifications in the CH3 domain that greatly reduce binding to, for example, Protein A. The sequences can include those described, for example, in WO2016 / 018740 and U.S. Pat. No. 8,586,713. One polypeptide of the dimer contains a mutation and the other polypeptide contains a mutation. For ease of illustration, mutations in the Fc domain are referred to herein as not including natural mutations. It may be referred to throughout as "star substitution" or Fc*. Thus, Fc*Fc* is a nucleotide sequence that contains both monomers. FcFc* or Fc*Fc indicates a heterodimer with respect to the Fc* substitution. The terms FcFc* and Fc*Fc are used interchangeably herein.
[0046] The term "mobile phase modifier" refers to a non-specific (i.e., non-affinity) interface between proteins. Reduce the effects of covalent or other non-covalent interactions, or "Mobile phase modifiers" include, for example, salts, Group I and and Group II metals with acetate, bicarbonate, carbonate, and halogens (e.g., chloride ions). Ionic bonds with cations, phosphate ions, or sulfate ions A non-limiting exemplary list of "mobile phase modifiers" includes beryllium, lithium, Acetates of sodium and potassium; sodium and potassium bicarbonates; charcoal Lithium carbonate, sodium carbonate, potassium carbonate, and cesium carbonate; lithium chloride, chloride Sodium, potassium, cesium, and magnesium chlorides; sodium fluoride and potassium fluoride; sodium nitrate, potassium nitrate, and calcium nitrate; phosphoric acid sodium and potassium phosphates; and calcium and magnesium sulfates. nothing.
[0047] "Mobile phase modifiers" also weaken or otherwise interfere with non-covalent binding forces, and thus improve the bioavailability of biological Chaotropic agents include those that increase the entropy within a molecular system. Non-limiting examples include butanol, calcium chloride, ethanol, guanidinium chloride, Lithium perchlorate, lithium acetate, magnesium chloride, phenol, propanol, dodecane Chaotropic agents include sodium silyl sulfate, thiourea, and urea. Salts that affect the solubility of proteins include: For example, chloride ions, nitrate ions, bromide ions, chlorate ions, iodide ions, peroxide ions, These include the chlorate ion, and the thiocyanate ion. Examples include lithium, magnesium, calcium, and guanidinium. can be done.
[0048] "Mobile phase modifiers" include those that affect ionic or other non-covalent interactions. and protein addition to the pH gradient or pH step, or in the "mobile phase modifier" Upon equilibration of the InA support and application of a pH step or pH gradient, homodimeric IgG and and heterodimeric IgG (e.g., wild-type human IgG and the same IgG but as described herein). The pH unit distance between the elution of the β-terminal end of the β-terminal end of the CH3 domain (which has one or more modifications of its CH3 domain as shown in The appropriate concentration of the "mobile phase modifier" is determined based on the same column, pH stage, and Using a pH step or gradient, the maximum pH distance for a given pH step or gradient is Increase the concentration of the "mobile phase modifier" until the concentration reaches "Mobile phase modifier" can also include non-polar modifiers, such as propylene glycol. These include alcohol, ethylene glycol, etc.
[0049] Affinity matrices include, for example, Protein A, Protein G, Protein L, A solid support to which an affinity protein, such as ribozyme Z, or a recombinant derivative thereof, is attached. Such supports are non-aqueous matrices that support the cellular functions (Choe, W., et al., 2016, supra). These include agarose, sepharose, glass, silica, polystyrene, nitrocellulose, Examples of suitable materials include charcoal, sand, cellulose, and any other suitable materials. The second protein can be attached to a solid support using any suitable method well known in the art. Methods for immobilizing proteins on suitable solid supports are known in the art. See, for example, Guide to Protein Purification, Methods in See Ostrove in Enzymology, 182:357-371, 1990. Such solid supports, with or without InA, are available from, for example, Vector Laboratory (Calipharma, CA). Burlingame, California; Santa Cruz Biotechnology, Santa Cruz, California (New Jersey), BioRad (Hercules, CA), Amersham Biosciences (Sweden), Denver (part of GE Healthcare in Uppsala), Pall (Port Washington, New York), and EMD-Millipore (Billerica, MA), among many other commercial sources. Protein A immobilized on a pore glass matrix is readily available from PROSE. It is commercially available as P®-A (Millipore). The solid phase is an agarose-based matrix. Protein A immobilized on an agarose matrix may be, for example, MABSE. It is commercially available as LECT™ (GE Amersham Biosciences). Immunoglobulin binding or F Affinity columns containing binding proteins are used to detect either SpA or SpA mimetic ligands. The nucleic acid may be prepared by immobilizing either one on a solid support.
[0050] As used herein, "affinity chromatography" refers to To perform a quantitative separation, general characteristics of biomolecules such as isoelectric point, hydrophobicity, or size are considered. A chromatographic method that exploits specific, reversible interactions between biomolecules rather than their affinity for one another. "Protein A affinity chromatography" or "Protein A Chromatography" "Topography" refers to the binding of the IgG-binding domain of Protein A to the Fc portion of an immunoglobulin molecule. This is a specific affinity chromatography method that utilizes the affinity of the Fc portion. , human or animal immunoglobulin constant domains CH2 and CH3, or substantially the same as these Contains similar immunoglobulin domains.
[0051] Protein A is a cell wall component produced by some strains of Staphylococcus aureus. It consists of a single polypeptide chain. The protein A gene product is involved in the cell wall of the pathogen. It consists of five tandemly linked homologous repeats. The five domains are approximately 58 amino acids in length. They are expressed as EDABC and each shows immunoglobulin binding activity (Tashiro M & Montelione G T (1995) Curr. Opin. Struct. Biol., 5(4): 471-481). Five homologous immunoglobulins The binding domains fold into a three-helical bundle. Each domain is expressed in many mammalian species. These proteins can bind to IgG, in particular (Hober S et al., (2007) J. Chroma togr. B Analyt. Technol. Biorned. Life Sci., 848(1): 40-47). Protein A is It binds to most immunoglobulin heavy chains within the Fc region, but in the case of the human VH3 family The antibody also binds within the Fab region (Jansson B et al, (1998) FEMS Immunol. Med. Microbiol. , 20(1): 69-78). Protein A is expressed in various species including humans, mice, rabbits, and guinea pigs. It binds to human IgG but not to human IgG3 (Hober S et al., (2007) supra). The inability of human IgG3 to bind to Protein A is due to the presence of H435R and Y436 in the Fc region of human IgG3. F substitution (EU numbering, Jendeberg et al., (1997) J. Immunol. Methods, 201(1): 25-34) Protein A interacts with IgG as well as IgM and IgA.
[0052] The ability of Protein A to bind antibodies with such high affinity is a key advantage in biopharmaceuticals. The driving force behind its industrial-scale use is the production of antibodies in biopharmaceuticals. The protein A used is usually produced recombinantly in E. coli and is a derivative of natural protein A. (Liu HF et al., (2010) MAbs, 2(5):480-499). In general, recombinant Protein A is used as a stationary phase chromatography resin for the purification of antibodies. Optimal binding occurs at pH 8.2, but binding is not observed under neutral or physiological conditions (pH 7.0-7.6). Elution is usually achieved by a pH shift to an acidic pH (glycine-HCl, pH 2.5-3.0). This is achieved by almost completely removing the protein without permanently affecting its structure. Effectively dissociates most protein-protein and antibody-antigen binding interactions Nevertheless, some antibodies and proteins are damaged by low pH and may In some cases, immediately after harvesting, add 1 / 10 volume of an alkaline buffer such as 1 M Tris-HCl, pH 8.0. It may be best to neutralize by reducing the pH of the solution and minimizing the duration in low pH conditions.
[0053] There are a variety of commercially available resins for Protein A chromatography. The main differences between the media are the type of support matrix, protein A ligand modification, and pore size. and particle size. These factors vary depending on the compressibility, chemical and This results in differences in physical robustness, diffusion resistance and binding capacity (Hober S et al., supra). l., (2007)). An example of a Protein A chromatography resin is the GE Healthcare MabSelect SuRe™ Protein A resin and MabSelect™ Protein A resin, Econo from BioRad Pac Protein A columns, rProA available from Applied Biosystems, and Examples of suitable ion exchangers include, but are not limited to, Thermo Fisher's POROS® A. Not done.
[0054] Protein A used here is a native protein derived from the cell wall of Staphylococcus aureus. quality, recombinantly or synthetically produced Protein A, and the ability to bind to the Fc region The engineered protein A includes, for example, a mutant that retains the Z domain tetramer. The protein A is a tetramer of the Y domain, or an engineered protein A lacking the D and E domains. These examples of engineered Protein A are the VH3 domain of immunoglobulins. cannot bind (or if it does, it binds with very low affinity) ), but is still able to bind to the CH3 domains of IgG1, IgG2 and IgG4. In practice, Protein A chromatography involves the use of Protein A immobilized on a solid support. Gagnon, Protein A Affinity Chromatography, Purification Tool See s for Monoclonal Antibodies, pp. 155-198, Validated Biosystems, 1996.
[0055] Protein G is a bacterial cell wall protein isolated from group C and group G streptococci. DNA sequencing of native protein G isolated from various streptococci revealed that it is a The cytochrome P450 binding domain and the sites for albumin and cell surface binding were identified. In response, both the immunoglobulin-binding domain and the albumin-binding domain are divided into 2-3 independent fragments. (Tashiro M & Montelione GT (1995) Curr. Opin. Stru ct. Biol., 5(4): 471-481). Protein G from G148 strain contains ABD1, ABD2, and It contains three albumin-binding domains, ABD3 and C1, C2, and C3, and an immunoglobulin G domain. It consists of a phosphorus-binding domain (Olsson A et al., (1987) Eur. J. Biochem., 168(2): 319- 324.) Each immunoglobulin-binding domain, designated C1, C2, and C3, is approximately 55 residues long. and separated by a linker of about 15 residues. Protein G immunoglobulin binding domain All experimentally solved 3D structures of It exhibits a very compact globular structure without any missing groups (Sauer-Eriksson AE et al, (1 995) Structure, 3(3): 265-278; Derrick JP & Wigley DB (1992) Nature, 359(6397) : 752- 754; Derrick JP & Wigley DB (1994) J Mol. Biol, 243(5): 906-918; Lian L Y et al. (1994) Nat. Struct. Biol., 1(6): 355-357). This structure is It contains a four-stranded beta sheet composed of two antiparallel beta hairpins linked by a tether.
[0056] Streptococcus strains from groups C and G, in contrast to protein A, are highly resistant to IgG, including IgG3. Protein G also binds to all human subclasses. It also binds to several animal IgGs, including IgG (Bjorck I. & Kronvall G (1984) J. Immunol, 133 (2): 969-974; Akerstrom B et al, (1985) J. Immunol, 135(4): 2589-2592; Akerstrom B & Bjorck L (1986) J. Biol. Chem , 261(22): 10240-10247, Fahnestock SR et al, (1986) J. Bacteriol, 167(3): 870-880). Thus, protein G is a It shows a broader binding spectrum to different species subclasses compared to Protein G binds with high affinity to the Fab portion of IgG. The main structures are known both alone (by NMR, Lian LY et al., (1994) supra) and with IgG1 Fab. Complex (X-ray crystallography, Derrick JP & Wigley DB (1992) supra and Derrick J All experimentally solved 3D structures have been determined by both the NMR spectroscopy and the NMR spectroscopy (P & Wigley DB (1994)). demonstrated binding within the CH1 domain of the IgG heavy chain.
[0057] Protein G, as used herein, refers to naturally occurring or engineered streptococcal protein. It may be protein G or may be engineered protein G. The protein G may contain the B1 domain (also known as GB1) and may be conjugated or non- In another embodiment, the second affinity matrix may be conjugated. The protein L ligand and its derivatives are immobilized on a solid substrate. Similar to protein A, recombinant protein G produced in E. coli is used to purify antibodies. The albumin binding domain and the cell surface binding domain can be used to reduce non-specific binding. The main components have been removed from recombinant Protein G, and therefore, the IgG was isolated from the crude sample. Similar to Protein A, recombinant Protein G can be used for the purification of antibodies. Optimal binding occurs at pH 5, but binding can be slowed down by binding to stationary phase chromatography resins. The pH shift to acidic pH is also favorable at pH 7.0-7.2; as with Protein A, elution also occurs (glycine-HCl, pH 2.5-3.0). Protein G Chromatography Examples of lipids include, but are not limited to, Protein G Sepharose from GE Healthcare. Examples include the Sucrose™ 4 Fast Flow resin and the HiTrap™ Protein G HP column. do.
[0058] Similar to Protein A, recombinant Protein G produced in E. coli has been used to purify antibodies. It is routinely used to bind albumin to reduce nonspecific binding. The cleavage domain and cell surface binding domain have been removed from the recombinant Protein G, and thus the crude It can be used to isolate IgG from a sample. Similar to Protein A, recombinant protein Tein G is coupled to a stationary phase chromatography resin for the purification of antibodies. Binding occurs at pH 5, but binding is also good at pH 7.0-7.2; as with Protein A, Elution is also achieved by a pH shift to an acidic pH (glycine-HCl, pH 2.5-3.0). An example of an in-G chromatography resin is Protein G Sepharose from GE Healthcare ( ™ 4 Fast Flow resin and HiTrap™ Protein G HP columns, Applied Biosystem rProG available from Thermo Fisher Scientific, Inc., and, as shown in the Examples, POROS from Thermo Fisher Scientific. (registered trademark) G.
[0059] Other proteins, such as protein L, M1 protein, and protein H, may also be used in the methods of the present invention. It can be used in affinity chromatography. Protein L is originally derived from cellular It is an immunoglobulin-binding protein derived from the bacterium Peptostreptococcus magnus, but is currently It is produced by recombinant means in (Bjorck L (1988) J. Immunol., 140(4): 1 194-1197, Kastern W et al. (1992) J. Biol. Chem., 267(18): 12820-12825). Protein L is Unique binding via kappa light chain interactions without interfering with the antigen-binding site of the antibody (Nilson BH et al., (1993) J. Immunol. Methods, 164(1): 33-40). This gives Protein L a broader range of immunoglobulin binding domains than other antibody-binding proteins. Protein L confers the ability to bind to all classes and subclasses of immunoglobulins. Protein L also binds to IgG, IgM, IgA, IgE, and IgD. It also binds to scFv and Fab fragments (Nilson BH et al., supra). (1993);Bottomley SP et al., (1995) Bioseparation, 5(6): 359-367). Protein L represents the human variable domains of the kappa I, III and IV subclasses and the mouse kappa I subclass. (Nilson BH et al., (1992) supra). Protein L chromatography tree An example of a lipid is Protein L resin from Genescript, which is used in the examples. However, it is not limited to this.
[0060] The M1 protein and protein H are co-localized on the surface of certain strains of Streptococcus pyogenes. Protein H is a surface protein present on the surface of the IgG. Protein H has affinity for the Fc region of IgG (Akesso n P et al., (1990) Mol. Immunol., 27(6): 523-531; Akesson P et al., (1994) Bioch em. J., 300 (Pt 3): 877-886). Protein H binds to the Fc region of human, monkey, and rabbit IgG. (Akesson P et al., (1990), supra; Frick IM et al., (1995) EMBO J., 14(8) : 1674-1679). M protein is also known to bind to fibrinogen (Kantor et al., 2003). FS (1965) J Exp Med, 121: 849-859), previous studies have shown that the M1 protein from API strains is It was also shown to have affinity for IgG and polyclonal IgG (Schmidt KH & Wadstrom T (1990) Zentralbl. Bakteriol., 273(2): 216-228).
[0061] Affinity chromatography can also be used to detect the affinity of antibodies, antibody fragments, or immunoglobulins. Selectively bind and purify chimeric fusion proteins containing the domains and / or sequences of The antibodies include IgG, IgA, IgM, IgY, and other types of antibodies. Antibodies include IgA, IgD, and IgE types. Antibodies are also known as camelid antibodies, genetically engineered camelid antibodies, and Also included are single chain antibodies such as dasmolytic antibodies, single chain antibodies, single domain antibodies, nanobodies, etc. Antibody fragments include VH, VL, CL, and CH sequences. Antibody fragments and fusion tags containing antibody sequences Examples of the proteins include F(ab')3, F(ab')2, Fab, Fc, Fv, dsFv, (scFv)2, scFv, scAb, minibody, diabody, triabody , tetrabodies, Fc fusion proteins, trap molecules, etc. (See ar et al., Methods 56 (2012): 116-129). The fluorophores are suitable for antibodies, their fragments, and fusion proteins containing these fragments. Such ligands may include ligands that are directed to target molecules. Examples of such antibodies include antibody-binding proteins, bacterial receptors, antigens, lectins, or anti-antibodies. For example, IgG-CH1, IgG-Fc, and IgG-C are used as affinity ligands. H3, IgG1, LC-kappa, LC-lambda, IgG3 / 4, IgA, IgM, etc. Affinity ligands from the family Mycorrhizae can be used (Carl's, CA). Available commercially as CAPTURESELECT chromatography resin from Bud Life Technologies. (I).
[0062] from homodimers based on the different affinities of the heterodimers to affinity reagents. A technique has been described that facilitates the recovery of heterodimers of . This involves the use of two different heavy chains from two different animal species, One does not bind to protein A (Lindhofer H et al., (1995) J Immunol., 155(1): 21 The same authors also identified two different human immunoglobulin isotypes (IGHG1 and IGHG 3) two different heavy chains, one of which (IGHG3) binds to protein A. The use of non-compatible glycerols has also been described (U.S. Patent No. 6,551,592, Lindhofer H et al. A variation of the latter technique is described in WO10 / 151792 (Davis S et al.), which In order to greatly reduce the affinity of one of the heavy chains of the heterodimer for Protein A, Jendeberg et al. (1997) J. Immunol. Methods, 201(1): 25- This involves the use of two amino acid substitutions, H435R / Y436F, described by 34 I did.
[0063] As used herein, the term "detector" refers to a detector that detects the amount of eluate from a chromatography column. Chromatograph equipped with means for detecting and / or evaluating components of the mixture output Two types of detectors are known in the art: destructive and non-destructive. Common types of detectors are known: Destructive detectors involve continuous conversion ( Combustion, vaporization, or mixing with a reagent) and then the resulting material (plasma, aerosol, etc.) The nondestructive detector measures some physical property of the column solution (sol or reaction mixture). Directly measure some property of the exudate (e.g., UV absorption) and thus allow for further analytical recovery Examples of destructive detectors are the Charged Aerosol Detector (CAD), Flame Ionization Detector (FID), and the Electrochemical Detector (ECD). FID, NQA, FPD, Atomic Emission Detector ED), nitrogen phosphorus detector (NPD), evaporative light scattering detector (ELSD), mass spectrometer (MS), electrochemical These include the electroluminescent detector (ELCD), the summon detector (SMSD), and the Mira detector (MD). An example of a destructive detector is a UV detector, including fixed length and variable length UV detectors. , including diode array detectors (DAD) or photodiode array (PDA) detectors. The UV absorption of the effluent can be measured continuously at single or multiple wavelengths. Other examples of detectors are thermal conductivity detectors (TCD), fluorescence detectors (FLR), electron capture detectors, and photodetectors. A photoionization detector (PID), and a refractive index detector (RI or RID). A DAD / UV detector can be utilized to detect and quantify the eluted material flowing from the column compartment. Bispecific FcFc* antibodies, FcFc homodimers, and Fc*Fc* heterodimers are chromatographically -Selectively elutes from the system and the signal is detected by UV detection at 280 nM. The vessel may be a temperature controlled flow cytometer with cooling capabilities that allow for improved stability of, for example, proteinaceous materials. Like the cell, it may be adapted to be connected to a temperature control system.
[0064] The present invention can be implemented, for example, using commercially available chromatography systems (e.g., Shimadzu Corporation, Agilent Te Chromatography systems such as those available from Chromatography Technologies, Waters Corporation, etc. In one non-limiting embodiment, the Such systems are particularly suited to solvent and / or reagent holding units, solvent managers / pumps, The system includes a sample manager, a column compartment manager, and a detector unit. A non-limiting embodiment is shown in FIG.
[0065] The retention unit stores the solvents and buffers used in chromatography applications. In one embodiment, the solvent and buffer are stored in a solvent manager. The mixture passes through a solvent degasser before flowing into the evaporator.
[0066] The solvent manager is responsible for the delivery of solvents and distributes them to each specific A computer program that can be configured to meet the needs of the analytical system according to the present embodiment. The solvent management module may include, for example, a two-way or four-way gradient module. The jars can, among other things, control the solvent velocity, buffer composition, and pressure limits of the HPLC system. do.
[0067] The sample manager can optionally vary the temperature (e.g., cooling and / or heating). ), or maintaining a constant temperature of the sample before loading it onto the column (e.g. In one embodiment, the sample may include a temperature control unit capable of cooling the sample to a desired temperature. The samples are contained in the sample manager compartment and kept at 4°C while waiting to be injected. The needle is then sent to the sampler where it is fed directly to the sample shown in the queue. In an embodiment, the autosampler detects the overflow of injected solvent and / or sample. The sample is then dispensed from the autosampler needle. Go to the Columns section.
[0068] The amount, or quantity, of protein in a fraction is measured by passing the protein through a detector. Proteins can be eluted and determined using calculation methods known in the art. The system may further include a system control unit or other computer-aided device. do.
[0069] Purity and / or quality control analysis analyzes the ratio of three protein species present in a sample The purity of the protein in the mixture is determined by the amount of each protein fraction. Determine the amount of the protein of interest and calculate the ratio of the amount to the sum of the amounts of all proteins in the mixture. As an example, the heterodimeric protein and The purity of the heterodimeric protein in a mixture containing two or more protein impurities is determined by the following steps: determining the amount of the protein fraction containing the heterodimeric protein and the two or more protein impurities; The amount of the heterodimeric protein was quantified by calculating the ratio of the amount of the heterodimeric protein to the sum of the amounts of It can be made into
[0070] The metric bispecific purity is calculated relative to the total antibody amount as defined by Equation 1: The percentage of bispecific antibodies is given. Examples include FcFc, FcFc* and Fc*Fc*. The purity of FcFc* in a mixture containing Fc can be quantified as follows:
[0071] Equation 1: Quantification of bispecific antibody purity
number
[0072] As used herein, a diverter valve, flow diverter valve, or flow control valve is a chromatographic valve. - A means for directing, changing, or blocking the flow path of eluent from a column. The directional control valve may be of a multi-way type, for example, a two-way, three-way, four-way, etc. type, i.e., a directional control valve can direct the flow to two, three, or more different receivers. The receivers are It can be of any origin, for example, a chromatography column, an affinity chromatography column, The receiver may be a chromatographic column, a detector, or a waste disposal container. This is achieved by switching between different positions.
[0073] As an example, in a chromatography system, the switching valve may be The matrix, second affinity matrix, and detector can be arranged consecutively or non-consecutively. In a non-limiting embodiment, such as shown in FIGS. The valve serially connects the first affinity matrix to the second affinity matrix. In this exemplary system, one switching valve position directs the eluent to the first affinity column. From the T matrix to a second affinity matrix and then to the detector By switching the diverter valve to another position, the eluent is allowed to flow through the first Direct detection from the affinity matrix, bypassing the second affinity matrix The eluent from the second affinity matrix is allowed to flow into the first to the detector, with or without the affinity matrix of The second affinity matrix can also be directly connected to the autosampler. In another non-limiting embodiment shown in FIG. 4B, the first affinity mer The eluent from the trix bypasses the second affinity matrix and passes to the detector. Can flow directly.
[0074] In one aspect, the present invention utilizes a novel chromatography system that includes a switching valve. A method for quantitatively assessing the amount and / or purity of a heterodimer fraction by using Describe the following.
[0075] In one embodiment, the present invention provides a method for producing a protein comprising the steps of: Quantifying the amount and / or purity of a protein in a sample containing a mixture of protein impurities The present invention describes a method for isolating a first impurity from a first affinity matrix. The second impurity binds to the first affinity matrix and the second impurity does not substantially bind to the first affinity matrix. The second affinity matrix is bound to the antibody, the method comprising the steps of:
[0076] a. A first affinity matrix, a second affinity matrix, and a test applying the sample to a chromatography system including a detector, wherein a first The affinity matrix is connected to a second affinity matrix via a switching valve. continuously connected;
[0077] b. eluting a second impurity from the first affinity matrix under a first set of conditions; eluting the antibody onto an affinity matrix;
[0078] c. Switch the diverter valve to bypass the second affinity matrix and begin the second set. The proteins were eluted through the detector under the specified conditions, and the amount of eluted protein was determined. determining the
[0079] d. eluting the first impurity through a detector under a third set of conditions; determining the amount of pure matter;
[0080] e. separating the second impurity from the second affinity matrix under a third set of conditions. and determining the amount of the eluted second impurity; and
[0081] f. Quantifying the amount and / or purity of said protein in the sample.
[0082] In one embodiment, the protein is a multimeric protein, such as an antibody. In one embodiment, the protein is an antibody of interest, and the first and second protein impurities are Monomeric proteins, e.g., antibodies, which may or may not be structurally related to the antibody of interest. In one embodiment, the protein is a bispecific antibody, i.e., a heterodimeric protein. the first protein impurity is a first homodimeric protein and the second protein impurity is a The matrix impurity is a second homodimeric protein. In some cases, a mixture of multimeric proteins The article may be prepared by culturing multiple cells, e.g., Chinese Hamster Ovary (CHO) cells in cell culture. Produced by eukaryotic cells.
[0083] In one embodiment, the protein is a first affinity matrix. In one embodiment, the protein is a heterodimeric protein. the first protein impurity is a first homodimeric protein and the second protein impurity is a The matrix impurity is a second homodimeric protein, and the heterodimeric protein and the first homodimeric protein. The dimeric protein binds to the first affinity matrix and the second homodimeric protein The protein does not substantially bind to the first affinity matrix and does not bind to the second affinity matrix. Binds to Trix.
[0084] In one embodiment, the protein comprises a first immunoglobulin CH3 domain and a second immunoglobulin CH3 domain. an immunoglobulin CH3 domain, wherein the first and second immunoglobulin CH3 domains The affinity matrixes differ in their affinity to the first affinity matrix, and the sample The protein includes a protein having two first CH3 domains and a protein having two second CH3 domains. The present invention also includes mixtures comprising a protein containing insulin.
[0085] In one embodiment, the second CH3 domain comprises the amino acids H435R and Y436F (according to the EU numbering system). ; H95R / Y96F in the IMGT exon numbering system) amino acid substitutions.
[0086] In one embodiment, the first affinity matrix is a protein immobilized on a solid substrate. In some cases, the substrate is a bead or particle. The affinity matrix is thus a plurality of particles to which Protein A is immobilized. Protein A may be native or modified staphylococcal protein A, or may be a genetic The genetically engineered protein A may be, for example, Z domain tetramer, Y domain tetramer, or engineered tetramer lacking the D and E domains Examples of these engineered protein A's include immunoglobulins. It is unable to bind to the VH3 domain of Brin (or if it can, it has a very low affinity) Although it binds to the CH3 domain of IgG1, IgG2, and IgG4, can be done.
[0087] In one embodiment, the second affinity matrix is a protein immobilized on a solid substrate. In some cases, the substrate is a bead or particle. The affinity matrix is thus a plurality of particles to which Protein G is immobilized. Protein G may be a native or modified streptococcal protein G, or may be a genetic The genetically engineered protein G may be a B1 domain. (also known as GB1), which may be in conjugated or unconjugated form. In another embodiment, the second affinity matrix is immobilized on a solid substrate. The present invention includes Protein L Ligand and its derivatives.
[0088] In one embodiment, the elution conditions are determined by a specific pH range and the use of mobile phase modifiers (e.g., chaotropes). In one embodiment, the second impurity (e.g., a second phosphatase) may be present in the buffer. The first set of elution conditions for eluting the mono-dimeric protein comprises a first pH. In an embodiment, a second set for eluting a protein (e.g., a heterodimeric protein) is In one embodiment, the elution conditions for the first impurity (e.g., a first homodimer) include a second pH. The third set of elution conditions for eluting the soluble protein (soluble protein) comprises a third pH. In one embodiment, the second pH can be lower than the first pH. In one embodiment, the third pH is In one embodiment, the second pH is lower than the first pH and The pH of 3 can be lower than the second pH. In another embodiment, the first pH is lower than pH 5. high, or from about pH 5 to about pH 8, or from about pH 5.2 to about pH 7.4, or In one embodiment, the second pH is from about pH 3.5 to about pH 6, or about pH 3.8. In one embodiment, the third pH may be less than pH 4, or about pH 1.5. The pH may be from about pH 3.6, alternatively from about pH 2.0 to about pH 2.8, alternatively about pH 2.2.
[0089] In one embodiment, the first, second and third sets of elution conditions are performed using a suitable buffer, e.g. For example, citrate, acetate, 4-morpholineethanesulfonate (MES), phosphate, amber In one embodiment, the first, second and The third set of elution conditions includes a chaotropic agent. The chaotropic agent is lithium, A cation selected from magnesium, calcium, and guanidinium and a chloride ion. ions, nitrate ions, bromide ions, chlorate ions, iodide ions, perchlorate ions, and and a thiocyanate ion. In an embodiment, the chaotropic agent is CaCl2, for example, 250 to 500 mM CaCl2. In another specific embodiment, the chaotropic agent is MgCl2, for example, 250 to 50 0 mM MgCl2.
[0090] In one embodiment, the heterodimer is a bispecific antibody, wherein the first polypeptide The peptide comprises a CH3 domain capable of binding to protein A ("Fc") and a second polypeptide. If the peptide contains a CH3 domain that is not capable of binding to Protein A ("Fc*"). In some cases, the second polypeptide has the sequence H435R / Y436F (according to the EU numbering system; IMGT It contains substitutions in its CH3 domain (referred to as "Fc*" or "StMc*"), H95R / Y96F in Chthon numbering. (Also referred to as "substitution"). Thus, in some embodiments, the first homodimer comprises: A monospecific antibody having two unsubstituted CH3 domains (i.e., FcFc); The Fc complex is a monospecific antibody having two H435R / Y436F substituted CH3 domains (i.e., Fc *Fc*); the heterodimer consists of one unsubstituted CH3 domain and one H435R / Y436F substituted CH3 domain. It is a bispecific antibody having both an Fc and an Fc domain (i.e., Fc*Fc).
[0091] In another embodiment, the present invention provides a method for the preparation of a heterodimeric protein comprising the steps of: of a heterodimeric protein in a sample containing a mixture of the protein and a second homodimeric protein. Methods for quantifying the amount and / or purity of heterodimeric proteins are described, where The first homodimeric protein binds to the Protein A matrix, while the second homodimeric protein binds to the Protein A matrix. The meric protein does not substantially bind to the Protein A matrix, but does bind to the Protein G matrix. The method comprises the steps of:
[0092] a. A chromatograph including a Protein A matrix, a Protein G matrix, and a detector. applying the sample to a chromatographic system, wherein the Protein A matrix the filter is continuously connected to the Protein G matrix via a switching valve;
[0093] b. A second homodimeric protein is eluted from the Protein A matrix under a first set of conditions. eluting the chromatographically isolated ...
[0094] c. Switch the diverter valve to bypass the Protein G matrix and run a second set of conditions. The heterodimeric protein was eluted through a detector under a pH of 10 and the amount of eluted protein was determined. determining the
[0095] e. Eluting the first homodimeric protein through the detector under a third set of conditions; determining an amount of the first impurity released;
[0096] e. The second homodimeric protein is coupled to a second affinity matrix under a third set of conditions. eluting the second impurity from the column through a detector and determining the amount of the eluted second impurity; and Beauty
[0097] f. Quantifying the amount and / or purity of the protein in the sample.
[0098] Differential affinity of the first homodimer and heterodimer to the second affinity matrix The binding depends, inter alia, on the pH and / or the concentration of the solution passed over the affinity matrix. can be manipulated by changing the ionic strength. Addition of the agent results in the isolation of each dimer species in non-overlapping fractions from the second affinity matrix. In one embodiment, this enhances elution of each dimeric species, thereby increasing the purity of each dimeric species. A first homodimer, e.g., Fc*Fc*, has a first affinity in a buffer having a first pH. The antibody is eluted from the affinity matrix onto a second affinity matrix. The heterodimer, e.g., FcFc* heterodimer, is capable of reacting with the first heterodimer in a buffer having a second pH range. Directly from the first affinity matrix, bypassing the second affinity matrix. In one embodiment, the second homodimer, e.g., FcFc, is eluted in a third pH range into a contact detector. The first affinity matrix is separated from the second affinity matrix in a buffer having a range of In one embodiment, the first homodimer is eluted directly into the detector, bypassing the buffer. For example, Fc*Fc* is detected from a second affinity matrix in a buffer having a third pH. wherein the first pH range comprises a higher pH than the second pH range, and the second pH range comprises a higher pH than the first pH range. The first pH range includes a higher pH than the third pH range.
[0099] In one embodiment, to elute the second impurity (e.g., the second homodimeric protein), In one embodiment, the first set of elution conditions for eluting the protein (e.g., A second set of elution conditions for eluting a target protein (e.g., a heterodimeric protein) includes a second pH. In one embodiment, the first impurity (e.g., the first homodimeric protein) is eluted. The third set of elution conditions for the preparation of the elution product comprises a third pH. In one embodiment, the second pH is lower than the first pH. In one embodiment, the third pH can be lower than the second pH. In one embodiment, the second pH is lower than the first pH and the third pH is lower than the second pH. In another embodiment, the first pH is greater than pH 5, or from about pH 5 to about pH 8. Alternatively, the second pH may be from about pH 5.2 to about pH 7.4. In one embodiment, the second pH is from about pH 4 to about pH 5. or from about 4.2 to about 5.0. In one embodiment, the third pH may be less than pH 4. , or from about pH 2 to about pH 3.6, or from about pH 2.2 to about pH 2.8.
[0100] In one embodiment, a method for determining the amount and / or purity of FcFc* protein in a sample is provided. The method is disclosed, wherein the FcFc* protein comprises a first immunoglobulin CH3 domain (Fc ), fragments and / or derivatives thereof, and a second immunoglobulin CH3 domain (Fc*), and a fragment and / or derivative thereof, wherein the first and second immunoglobulin CH3 domains comprise: The first protein differs in its affinity for the affinity matrix, and the samples the FcFc* protein and a protein comprising two first CH3 domains (FcFc protein); and a protein containing two second CH3 domains (Fc*Fc* proteins). The method comprises the steps of: (a) applying the sample to a first protein affinity matrix under a first set of conditions; wherein said FcFc* protein and said FcFc protein are A first protein is bound to the affinity matrix, and the Fc* protein is substantially not binding to said first protein affinity matrix; (b) washing the first protein affinity matrix under a first set of conditions; The process of; (c) Conditions under which the Fc* protein binds to the second protein affinity matrix. The flow-through from step (a) and the wash solution from step (b) are then subjected to a second protein assay. applying a affinity matrix; (d) subjecting said second protein affinity to the same set of conditions as in step (c). - washing the matrix; (e) eluting the Fc* protein from the second protein affinity matrix. and determining the amount of eluted Fc* protein; (f) removing residual protein from the first protein affinity matrix under a second set of conditions. Elute the remaining bound Fc*Fc* protein and determine the amount of eluted Fc*Fc* protein. process; (g) binding to the first protein affinity matrix under a third set of conditions. eluting the eluted FcFc* protein and determining the amount of eluted FcFc* protein; (h) binding to the first protein affinity matrix under a fourth set of conditions. eluting the eluted FcFc protein and determining the amount of eluted FcFc protein; and (i) determining the amount and / or purity of FcFc* protein in a sample; Here, step (d) and / or step (e) are carried out simultaneously with steps (f) to (h) or after steps (f) to (h). This can be done before steps (f) to (h) or after steps (f) to (h).
[0101] In one embodiment, the amount and / or purity of a bispecific antibody (e.g., an FcFc* antibody) in a sample. Disclosed is a method for determining an FcFc* antibody comprising a first immunoglobulin heavy chain (Fc) and a second immunoglobulin heavy chain (Fc*), The heavy chains of the FcFc* antibodies differ in their affinity for Protein A, and the samples and antibodies that contain two first heavy chains (FcFc antibodies) and antibodies that contain two second heavy chains (Fc*Fc* antibodies). and a mixture comprising: (a) Under a first set of conditions, the sample was subjected to a Protein A affinity column (Protein A a column), wherein the FcFc* antibody and the FcFc antibody are The Fc* antibody binds to the Protein A column, whereas the Fc* antibody does not substantially bind to the Protein A column, The Protein A column is connected to the Protein G affinity column (Protein G column) via a switching valve. The flow-through from the Protein A column is directly fed to the Protein G column. wherein the Protein G column is further connected to an HPLC column; (b) The diverter valve was then switched so that the flow-through from the Protein A column was applied directly to the Protein G column. washing the Protein A column under a first set of conditions in a position such that the Protein A column is (c) washing the Protein G column under the same conditions as in step (b); (d) Elute the Fc*Fc* antibody from the Protein G column and determine the amount of eluted Fc*Fc* antibody. The process of; (e) Switching the switching valve to separate the Protein A column from the Protein G column. placing the column in position for connection to an HPLC column; (f) Eluting the remaining bound Fc* antibodies from the Protein A column under a second set of conditions. and determining the amount of eluted Fc* antibody; (g) eluting FcFc* antibodies bound to the Protein A column under a third set of conditions. determining the amount of eluted FcFc* antibody; (h) eluting FcFc antibodies bound to the Protein A column under a fourth set of conditions; determining the amount of eluted FcFc antibody; and (i) determining the amount and / or purity of FcFc* protein in a sample; Here, step (c) and / or step (d) are carried out simultaneously with steps (e) to (h) or after steps (e) to (h). This can be done before steps (e) to (h) or after steps (e) to (h).
[0102] In another embodiment, the protein is purified, analyzed, and / or the amount and / or quality of the protein is determined. In one embodiment, a chromatography system is provided for assessing the purity of the product. The chromatography system comprises a first affinity matrix, a second affinity matrix, a first affinity matrix, a second affinity matrix, and a detector, The affinity matrix and the detector are connected via a switching valve. In one embodiment, the first affinity matrix is a Protein A chromatograph. In one embodiment, the second affinity matrix can be a protease column. The column may be a tein G or protein L chromatography column.
[0103] In one embodiment, the detector is a UV detector, a charged aerosol detector, and / or a mass spectrometer. In one embodiment, the first affinity mercury is eluted from the first affinity mercury. The trix and the second affinity matrix are connected in series via a switching valve. In another embodiment, the first affinity matrix, the second affinity matrix , and the detector are all connected in series via a switching valve. The affinity matrix and the second affinity matrix are connected in series via a switching valve. The detector is connected to the first affinity matrix and the second affinity matrix. - The electrodes are non-continuously connected to the matrix.
[0104] In one embodiment, the method comprises: (i) a Protein A chromatography column; and (ii) a Protein A column. (iii) a UV detector, a charged aerosol detector, and / or and a detector including an HPLC column with a mass spectrometer. wherein the protein A chromatography column, the protein G chromatography column, The column and the detector are connected via a switching valve. EXAMPLES
[0105] The following examples illustrate specific aspects of the present description. The examples are merely embodiments and their various aspects. This document provides a specific understanding and implementation of the It's not good.
[0106] The chromatography experiments were performed in accordance with the configuration required to carry out the methods described herein. The HPLC system was equipped with an Agilent InfinityLab Quick Change valve. An example of a suitable valve is the Agilent Quick Change Valve. ve G4231A / C, G4232C / D, G4234A / C, G4236A / B, and G4238A / B. Non-limiting examples of valves suitable for practicing the present invention include the World Wide Agilent.com / cs / library / usermanuals / public / G4232- 90009 ValveKit TN EN. pdf, and Acquity UPLC Systems with 2D Technology Capabilities Guide, Revision A, Waters Corporation, 2012, each of which is incorporated by reference in its entirety. and is hereby incorporated by reference.
[0107] [Example 1]
[0108] The purity and quantity of the bispecific antibody in the mixture containing the two contaminating homodimers was determined as follows: The titer chromatogram was shown in Figure 1. The peptides (IgG4 Fc-containing and IgG4-Fc*-containing) and the common light chain polypeptide were incubated in CHO cells. The resulting cell supernatant samples contained a mixture of homodimers and heterodimers. is subjected to high speed centrifugation to remove protein aggregates, According to the purification method described in PCT Publication WO2016 / 018740 published on February 4, 2016, The supernatant was subjected to affinity chromatography. FcFc* heterodimer and impurity products were isolated. That is, a sample of the purified product containing FcFc and Fc*Fc* homodimer was diluted with 0.5 M NaCl. 3 x 0.1 mL POROS® A 20 μm Protein A columns (rProA Protein A was loaded onto a 100% PBS (obtained from Applied Biosystems, # 2-1001-00). The column was fitted with 2 × 0.1 mL POROS® G 20 via a switching valve as shown diagrammatically in Figure 4A. μm Protein G column (rProG, available from Applied Biosystems, # 2-1002-00) and a standard UV detector (flow rate 2.0 mL / min, UV peak at 280 nm). detection).
[0109] Process related, such as CHO DNA or host cell proteins (HCPs) A series of washes were performed to remove contaminants. A pH 5.6 mobile phase containing 0.5 M CaCl2 was used. The mixture was eluted using 1000 μg / mL of Fc*Fc* homodimer, which bound both Protein A binding sites from the Fc region. Since rProA is missing, this product-associated impurity is expected to flow past rProA onto rProG. On the other hand, bispecific FcFc* and FcFc homodimers are predicted to be retained on rProA. Ta.
[0110] Then, the switching valve was switched to take rProG offline and connect rProA directly to the detector. Next, a dual-specific mobile phase containing 0.5 M calcium chloride was used, pH 3.8-5.6 (molecule specific) The isomeric FcFc* antibodies were selectively eluted from rProA to the detector while the FcFc impurities were It was retained due to its stronger binding compared to the bispecific FcFc* antibody, and the amount of FcFc* was calculated. The FcFc impurity was then separated from rProA by a pH 2.2 mobile phase containing 0.5 M calcium chloride. The FcFc was selectively eluted into the eluate and the amount of FcFc was calculated.
[0111] Then, switch the switching valve back to connect rProG online continuously and connect rProA to rProG. The rProG was then connected to the detector. A pH 2.2 mobile phase containing 0.5 M calcium chloride was then added. The Fc*Fc* impurity was eluted into the detector using and the amount of Fc*Fc* was calculated.
[0112] The amount and purity of the FcFc* bispecific antibody is determined based on the total amount of FcFc, FcFc* and Fc*Fc* fractions. The ratio of Fc to Fc* fractions was determined.
[0113] The flow rate of the method, wash length, bispecific elution length, and % buffer in the elution step of the method Antibody C was studied and was thought to potentially have an effect on the recovery of all three antibody types. The parameters examined in this method and their roles are shown in Table 1 below. , and values.
[0114] Table 1: Bispecific purity robustness factors [Table 1]
[0115] Table 2 below shows the results of the present study evaluating the purity and quantity of three antibody samples: IgG*1, IgG4*A and IgG4*B. 1 shows various sets of operating conditions for the method of the invention.
[0116] Table 2: Bispecific purity robustness run conditions [Table 2]
[0117] Various modifications may be made to the subject matter described above without departing from the scope and spirit of the invention. As such, all of the above description or the appended claims are intended to be within the spirit and scope of the present invention. All subject matter is intended to be construed as illustrative and illustrative of the present invention. Many modifications and variations of the present invention are possible in light of the above teachings. It is intended to embrace all such alternatives, modifications and variations which fall within the scope of the appended claims. It is intended to
[0118] All patents, applications, publications, test methods, literature, and other materials cited herein are the property of their respective owners. Each of the above-mentioned references is incorporated herein by reference in its entirety as if physically present in the present specification. Be absorbed.
Claims
1. A sample containing a mixture of a protein, a first protein impurity, and a second protein impurity.
1. A method for quantifying the amount and / or purity of said protein in a sample, comprising: wherein the protein and the first impurity are bound to a first affinity matrix. and the second impurity is not substantially bound to the first affinity matrix and is a second impurity. The method comprises the steps of: a. the first affinity matrix and the second affinity matrix. and applying the sample to a chromatography system comprising a detector; The first affinity matrix is connected to the second affinity matrix via a switching valve. a step of connecting the b. removing said second impurity from said first affinity matrix under a first set of conditions. eluting the entity onto said second affinity matrix; c. switching the diverter valve to bypass the second affinity matrix. The protein is then eluted through the detector under a second set of conditions. determining the amount of protein; d. eluting the first impurity through the detector under a third set of conditions; determining the amount of the first impurity detected; e. removing the second impurity from the second affinity matrix under a third set of conditions. eluting the substance through the detector and determining the amount of the eluted second impurity; and f. Quantifying the amount and / or purity of said protein in said sample.
2. The protein is coupled to the first affinity matrix by a first impurity The method of claim 1, wherein the .alpha.-
3. The protein is a heterodimeric protein, and the first protein impurity is a first a homodimeric protein, and said second protein impurity is a second homodimeric protein. wherein the heterodimeric protein and the first homodimeric protein are The second homodimeric protein binds to an affinity matrix and binds to the first homodimeric protein. substantially does not bind to the first affinity matrix and does not bind to the second affinity matrix. The method according to claim 1 or 2, wherein the binding is carried out.
4. The protein comprises a first immunoglobulin CH3 domain and a second immunoglobulin CH3 domain. the first and second immunoglobulin CH3 domains comprising the first affinity - Different in affinity to the matrix, the sample contains the protein and two A protein containing a first CH3 domain and a protein containing two second CH3 domains.
3. The method of claim 1 or 2, comprising a mixture comprising:
5. The method of claim 4, wherein the second CH3 domain comprises H435R and Y436F amino acid substitutions. Law.
6. The method of any one of claims 1 to 5, wherein the protein is an antibody.
7. The method of claim 6 , wherein the protein is a bispecific antibody.
8. The first affinity matrix comprises Protein A and the second affinity matrix comprises Protein A. The method according to any one of claims 1 to 7, wherein the matrix comprises Protein G.
9. The first set of conditions comprises a first pH, the second set of conditions comprises a second pH, 9. The method of claim 1, wherein the third set of conditions comprises a third pH.
10. The method according to claim 9, wherein the second pH is lower than the first pH and the third pH is lower than the second pH. The method described.
11. said first pH is from about pH 5.0 to about pH 7.4 and said second pH is from about pH 4.3 to about pH 5.6; 11. The method of claim 9 or 10, wherein the third pH is from about pH 2.0 to about pH 2.
8.
12. the first set of conditions, the second set of conditions, and the third set of conditions The method of any one of claims 1 to 11, comprising a mobile phase modifier.
13. The mobile phase modifiers include LiCl, NaCl, KCl, MgCl 2 , and CaCl 2 A salt selected from buffering agents The method of claim 12 which is a buffer.
14. A heterodimeric protein, a first homodimeric protein, and a second homodimeric protein. Quantifying the amount and / or purity of the heterodimeric protein in a sample containing a mixture of the heterodimeric protein and a target substance. A method for producing a compound comprising the steps of: wherein the heterodimeric protein and the first homodimeric protein are proteins. and said second homodimeric protein is bound to a Protein A matrix. and binding to a Protein G matrix without substantially binding to the oxalate, said method comprising the steps of: nothing: a. a method comprising: applying the sample to a chromatography system including a Protein A primer; The tricks are continuously connected to the Protein G matrix via a switching valve. ; b. Removing the second homodimer tag from the Protein A matrix under a first set of conditions. eluting the protein onto the Protein G matrix; c. switching the diverter valve to bypass the Protein G matrix; The heterodimeric protein is eluted through the detector under two sets of conditions. determining the amount of protein detected; d. dissolving the first homodimeric protein through the detector under a third set of conditions. and determining the amount of the eluted first impurity; e. removing said second homopolymer from said second affinity matrix under a third set of conditions. The dimeric protein is eluted through the detector and the amount of the eluted second impurity is determined. and f. Quantifying the amount and / or purity of said protein in said sample.
15. The heterodimeric protein comprises FcFc* and the first homodimeric protein comprises FcFc.
15. The method of claim 14, wherein the second homodimeric protein comprises Fc*Fc*.
16. A first affinity matrix, a second affinity matrix, and a detector. a first affinity matrix; The second affinity matrix and the detector are each connected to a switching valve. A connected chromatography system.
17. (i) Protein A chromatography column; and (ii) Protein G chromatography. (iii) a UV detector, a charge aerosol detector, and / or a mass spectrometer. and a detector comprising an HPLC column comprising the protein. the Protein A chromatography column, the Protein G chromatography column, and the A chromatography system, each of the detectors being connected via a switching valve.
Citation Information
Patent Citations
Chromatography system with guard column
JP2014501911A
Chromatography device and chromatography method
JP2015052533A
Chromatography
JP2015520667A
Purification platform for bispecific antibodies
JP2017524740A
Method for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
JP2018512431A
